BioMarin Pharmaceutical (BMRN) announced that Alexander Hardy has been named president and CEO, succeeding Jean-Jacques Bienaime, who will retire as chairman and CEO effective December 1, 2023. Hardy, currently the CEO of Genentech, will also serve as a director on BioMarin’s board of directors. Richard Meier, BioMarin’s lead independent director, will assume the role of chair of the board of directors. Hardy brings more than 30 years of experience in the global healthcare and biotechnology industries, most recently serving as CEO of Genentech, a member of the Roche Group (RHHBY).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMRN:
- BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
- Notable companies reporting after market close
- BMRN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Pinterest upgraded, Salesforce downgraded: Wall Street’s top analyst calls
- BioMarin upgraded to Market Perform from Underperform at Bernstein